keyword
MENU ▼
Read by QxMD icon Read
search

Oncotype Dx

keyword
https://www.readbyqxmd.com/read/28937963/ki67-and-lymphocytes-in-the-pretherapeutic-core-biopsy-of-primary-invasive-breast-cancer-positive-markers-of-therapy-response-prediction-and-superior-survival
#1
REVIEW
Claus M Schlotter, Lothar Tietze, Ulf Vogt, Carlos Villena Heinsen, Antje Hahn
Background Core needle biopsy plays a crucial role as diagnostic tool for BC. Both Ki67 and likely tumor-infiltrating lymphocytes (TILs) in the near future are determining the kind of systemic therapy. The role of TILs in BC is still an issue for clinical research, albeit preliminary results of neoadjuvant and adjuvant clinical studies already now highlight the crucial impact of TILs on therapy response and survival. Methods Evaluation of related publications (pubmed) and meeting abstracts (ASCO, SABCS). Results The monoclonal antibody Ki67 recognizing a nuclear antigene in proliferating cells is a positive marker of therapy response and superior survival...
September 22, 2017: Hormone Molecular Biology and Clinical Investigation
https://www.readbyqxmd.com/read/28898988/comparison-of-oncotype-dx-with-modified-magee-equation-recurrence-scores-in-low-grade-invasive-carcinoma-of-breast
#2
Yanjun Hou, Debra L Zynger, Xiaoxian Li, Zaibo Li
Objectives: Several specific histologic types of invasive carcinoma of breast, including invasive tubular carcinoma (ITC), invasive mucinous carcinoma (IMC), and classical invasive lobular carcinoma (CILC), are considered low-grade carcinomas with favorable outcomes. We aimed to investigate the utility of Oncotype DX test in these tumors by comparing its recurrence score (RS) with the modified Magee equation RS. Methods: Oncotype DX RSs were collected and modified Magee equation RSs were calculated in 163 low-grade invasive breast carcinomas, including 105 CILCs, 41 ITCs, and 17 IMCs...
August 1, 2017: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28885890/qualitative-radiogenomics-association-between-oncotype-dx-test-recurrence-score-and-bi-rads-mammographic-and-breast-mr-imaging-features
#3
Genevieve A Woodard, Kimberly M Ray, Bonnie N Joe, Elissa R Price
Purpose To evaluate the association between Breast Imaging Reporting and Data System (BI-RADS) mammographic and magnetic resonance (MR) imaging features and breast cancer recurrence risk in patients with estrogen receptor-positive breast cancer who underwent the Oncotype DX assay. Materials and Methods In this institutional review board-approved and HIPAA-compliant protocol, 408 patients diagnosed with invasive breast cancer between 2004 and 2013 who underwent the Oncotype DX assay were identified. Mammographic and MR imaging features were retrospectively collected according to the BI-RADS lexicon...
September 8, 2017: Radiology
https://www.readbyqxmd.com/read/28882552/prognostic-and-predictive-biomarkers-in-breast-cancer-past-present-and-future
#4
REVIEW
Andrea Nicolini, Paola Ferrari, Michael J Duffy
Following a diagnosis of breast cancer, the most immediate challenges in patient management are the determination of prognosis and identification of the most appropriate adjuvant systemic therapy. Determining prognosis can best be addressed with a combination of traditional clinicopathological prognostic factors, biomarkers such as HER2/neu and specific multigene genes tests. Amongst the best validated prognostic multigene tests are uPA/PAI1, Oncotype DX and MammaPrint. Oncotype DX and MammaPrint, may be used for predicting outcome and aiding adjunct therapy decision making in patients with ER-positive, HER2-negative breast cancers that are either lymph node-negative or node positive (1-3 metastatic nodes), while uPA/PAI-1 may be similarly used in ER-positive, lymph node-negative patients...
September 4, 2017: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/28874120/the-association-between-smoking-and-breast-cancer-characteristics-and-outcome
#5
Hadar Goldvaser, Omer Gal, Shulamith Rizel, Daniel Hendler, Victoria Neiman, Tzippy Shochat, Aaron Sulkes, Baruch Brenner, Rinat Yerushalmi
BACKGROUND: Smoking is associated with an increased incidence of hormone receptor positive breast cancer. Data regarding worse breast cancer outcome in smokers are accumulating. Current literature regarding the impact of smoking on breast cancer characteristics is limited. We evaluated the impact of smoking on breast cancer characteristics and outcome. METHODS: This was a retrospective single center study. All women diagnosed from 4/2005 through 3/2012 and treated in our institute for early, estrogen receptor positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer, whose tumors were sent for Oncotype DX analysis were included...
September 6, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28859291/relevance-of-spatial-heterogeneity-of-immune-infiltration-for-predicting-risk-of-recurrence-after-endocrine-therapy-of-er-breast-cancer
#6
Andreas Heindl, Ivana Sestak, Kalnisha Naidoo, Jack Cuzick, Mitchell Dowsett, Yinyin Yuan
Background: Despite increasing evidence supporting the clinical utility of immune infiltration in the estrogen receptor-negative (ER-) subtype, the prognostic value of immune infiltration for ER+ disease is not well defined. Methods: Quantitative immune scores of cell abundance and spatial heterogeneity were computed using a fully automated hematoxylin and eosin-stained image analysis algorithm and spatial statistics for 1178 postmenopausal patients with ER+ breast cancer treated with five years' tamoxifen or anastrozole...
February 1, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28855612/functional-proteomics-outlines-the-complexity-of-breast-cancer-molecular-subtypes
#7
Angelo Gámez-Pozo, Lucía Trilla-Fuertes, Julia Berges-Soria, Nathalie Selevsek, Rocío López-Vacas, Mariana Díaz-Almirón, Paolo Nanni, Jorge M Arevalillo, Hilario Navarro, Jonas Grossmann, Francisco Gayá Moreno, Rubén Gómez Rioja, Guillermo Prado-Vázquez, Andrea Zapater-Moros, Paloma Main, Jaime Feliú, Purificación Martínez Del Prado, Pilar Zamora, Eva Ciruelos, Enrique Espinosa, Juan Ángel Fresno Vara
Breast cancer is a heterogeneous disease comprising a variety of entities with various genetic backgrounds. Estrogen receptor-positive, human epidermal growth factor receptor 2-negative tumors typically have a favorable outcome; however, some patients eventually relapse, which suggests some heterogeneity within this category. In the present study, we used proteomics and miRNA profiling techniques to characterize a set of 102 either estrogen receptor-positive (ER+)/progesterone receptor-positive (PR+) or triple-negative formalin-fixed, paraffin-embedded breast tumors...
August 30, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28818434/adjusting-for-covariates-in-evaluating-markers-for-selecting-treatment-with-application-to-guiding-chemotherapy-for-treating-estrogen-receptor-positive-node-positive-breast-cancer
#8
Holly Janes, Marshall D Brown, Michael R Crager, Dave P Miller, William E Barlow
In many clinical contexts, biomarkers that predict treatment efficacy are highly sought after. Such treatment selection or predictive biomarkers have the potential to identify subgroups most likely to benefit from the treatment, and may therefore be used to improve clinical outcomes and reduce medical costs. A methodological challenge in evaluating these biomarkers is determining how to take into account other variables that predict clinical outcomes, or that influence the biomarker distribution, generically termed covariates...
August 14, 2017: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/28707056/comparison-of-oncotype-dx%C3%A2-recurrence-score%C3%A2-with-other-risk-assessment-tools-including-the-nottingham-prognostic-index-in-the-identification-of-patients-with-low-risk-invasive-breast-cancer
#9
Maura Bríd Cotter, Alex Dakin, Aoife Maguire, Janice M Walshe, M John Kennedy, Barbara Dunne, Ciarán Ó Riain, Cecily M Quinn
Oncotype DX® is a gene expression assay that quantifies the risk of distant recurrence in patients with hormone receptor positive early breast cancer, publicly funded in Ireland since 2011. The aim of this study was to correlate Oncotype DX® risk groupings with traditional histopathological parameters and the results of other risk assessment tools including Recurrence Score-Pathology-Clinical (RSPC), Adjuvant Risk Index (Adj RI), Nottingham Prognostic Index (NPI) and the Adjuvant! Online 10-year score (AO)...
July 14, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28664507/reducing-chemotherapy-use-in-clinically-high-risk-genomically-low-risk-pn0-and-pn1-early-breast-cancer-patients-five-year-data-from-the-prospective-randomised-phase-3-west-german-study-group-wsg-planb-trial
#10
Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E Kates, Michael Clemens, Wolfram Malter, Benno Nuding, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer, Andrea Stefek, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, Cornelia Liedtke, Calvin Chao, Steven Shak, Rachel Wuerstlein, Hans H Kreipe, Nadia Harbeck
BACKGROUND: The prospective phase 3 PlanB trial used the Oncotype DX(®) Recurrence Score(®) (RS) to define a genomically low-risk subset of clinically high-risk pN0-1 early breast cancer (EBC) patients for treatment with adjuvant endocrine therapy (ET) alone. Here, we report five-year data evaluating the prognostic value of RS, Ki-67, and other traditional clinicopathological parameters. METHODS: A central tumour bank was prospectively established within PlanB...
June 29, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28655121/high-grade-poorly-differentiated-neuroendocrine-carcinoma-of-the-breast-with-low-oncotype-dx-recurrence-score-a%C3%A2-case%C3%A2-report
#11
Carlos A Munoz-Zuluaga, Sandy Kotiah, Kimberley D Studeman
Primary neuroendocrine carcinoma of the breast (NECB) is a rare malignant tumor with controversial biological behavior and a lack of data guiding treatment decisions due to its scarcity. Cancer gene-expression profiling tests provide a better indication of clinical prognosis and help determine the best clinical management versus the traditional clinical and pathological parameters. This is a report of a NECB with a genetic assay that showed a low-risk tumor despite high-grade and poorly differentiated histopathological features...
June 23, 2017: Breast Disease
https://www.readbyqxmd.com/read/28640531/apparent-diffusion-coefficient-in-estrogen-receptor-positive-and-lymph-node-negative-invasive-breast-cancers-at-3-0t-dw-mri-a-potential-predictor-for-an-oncotype-dx-test-recurrence-score
#12
Sunitha B Thakur, Manuela Durando, Soledad Milans, Gene Y Cho, Lucas Gennaro, Elizabeth J Sutton, Dilip Giri, Elizabeth A Morris
PURPOSE: To measure the apparent diffusion coefficient (ADC) values in estrogen receptor-positive (ER+) and axillary lymph node-negative (LN-) invasive breast cancer and investigate the correlation of ADC with Oncotype Dx test recurrence scores (ODxRS). MATERIALS AND METHODS: This was a Health Insurance Portability and Accountability Act (HIPAA)-compliant single-site retrospective study. Patients underwent preoperative 3.0T MRI scans with additional diffusion-weighted imaging sequential scans (b = 0, 600 and b = 0, 1000 s/mm(2) ) from January 2011 to 2013...
June 22, 2017: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/28624063/acceptance-of-adjuvant-chemotherapy-recommendations-in-early-stage-hormone-positive-breast-cancer
#13
Emily F Marcinkowski, Rebecca Ottesen, Joyce Niland, Courtney Vito
BACKGROUND: The role of systemic chemotherapy in early-stage, estrogen receptor (ER)-positive, and Her2-negative breast cancer remains an area of active investigation. The decision to recommend chemotherapy is multifactorial, and some patients decline recommended chemotherapy. We sought to identify patient factors leading to refusal of adjuvant therapy. MATERIALS AND METHODS: Data were collected from National Comprehensive Cancer Network Outcomes database and used to identify patients with primary, unilateral, T1-T2, N0, ER+, Her2-disease diagnosed from 2005-2011...
June 15, 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/28615971/clinical-use-of-the-oncotype-dx-genomic-test-to-guide-treatment-decisions-for-patients-with-invasive-breast-cancer
#14
REVIEW
Terri P McVeigh, Michael J Kerin
Implementation of the Oncotype DX assay has led to a change in the manner in which chemotherapy is utilized in patients with early stage, estrogen receptor (ER)-positive, node-negative breast cancer; ensuring that patients at highest risk of recurrence are prescribed systemic treatment, while at the same time sparing low-risk patients potential adverse events from therapy unlikely to influence their survival. This test generates a recurrence score between 0 and 100, which correlates with probability of distant disease recurrence...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28607584/a-combined-ulbp2-and-sema5a-expression-signature-as-a-prognostic-and-predictive-biomarker-for-colon-cancer
#15
Secil Demirkol, Ismail Gomceli, Murat Isbilen, Baris Emre Dayanc, Mesut Tez, Erdal Birol Bostanci, Nesrin Turhan, Musa Akoglu, Ezgi Ozyerli, Sevi Durdu, Ozlen Konu, Aviram Nissan, Mithat Gonen, Ali Osmay Gure
Background: Prognostic biomarkers for cancer have the power to change the course of disease if they add value beyond known prognostic factors, if they can help shape treatment protocols, and if they are reliable. The aim of this study was to identify such biomarkers for colon cancer and to understand the molecular mechanisms leading to prognostic stratifications based on these biomarkers. Methods and Findings: We used an in house R based script (SSAT) for the in silico discovery of stage-independent prognostic biomarkers using two cohorts, GSE17536 and GSE17537, that include 177 and 55 colon cancer patients, respectively...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28606707/disparities-in-compliance-with-the-oncotype-dx-breast-cancer-test-in-the-united-states-a-national-cancer-data-base-assessment
#16
Zachary Kozick, Ammar Hashmi, James Dove, Marie Hunsinger, Tania Arora, Jeffrey Wild, Mohsen Shabahang, Joseph Blansfield
BACKGROUND: Oncotype DX (ODX) is a multi-gene tumor assay for breast cancer patients. Our objective is to assess whether eligible ODX patients received the test and whether recommendations were followed based on respective risk. METHODS: We retrospectively analyzed testing in patients deemed eligible for ODX using the National Cancer Data Base. RESULTS: A total of 158,235 patients met ODX eligibility criteria. Sixty-four percent of eligible patients did not receive the test...
June 9, 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/28548119/magee-equation-3-predicts-pathologic-response-to-neoadjuvant-systemic-chemotherapy-in-estrogen-receptor-positive-her2-negative-equivocal-breast-tumors
#17
Daniel J Farrugia, Alessandra Landmann, Li Zhu, Emilia J Diego, Ronald R Johnson, Marguerite Bonaventura, Atilla Soran, David J Dabbs, Beth Z Clark, Shannon L Puhalla, Rachel C Jankowitz, Adam M Brufsky, Barry C Lembersky, Gretchen M Ahrendt, Priscilla F McAuliffe, Rohit Bhargava
Magee Equations were derived as an inexpensive, rapid alternative to Oncotype DX. The Magee Equation 3 utilizes immunohistochemical and FISH data for estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki-67 for its calculation (24.30812+ERIHC × (-0.02177)+PRIHC × (-0.02884)+(0 for HER2 negative, 1.46495 for equivocal, 12.75525 for HER2 positive)+Ki-67 × 0.18649). We hypothesize that Magee Equation 3 scores from pre-therapy core biopsy can predict response to neoadjuvant systemic chemotherapy. A prospectively-maintained database of patients who received neoadjuvant systemic therapy from 2010 to 2014 at a single institution was retrospectively reviewed...
August 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28534000/improving-therapeutic-ratios-with-the-oncotype-dx%C3%A2-ductal-carcinoma-in-situ-dcis-score
#18
Nafisha Lalani, Eileen Rakovitch
Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer comprising nearly 25% of breast cancer diagnoses in the mammographic era. Current guidelines recommend breast-conserving surgery followed by adjuvant radiotherapy; however, controversy exists regarding the appropriateness of these recommendations. Some women with DCIS will never recur, which raises the concern of over-treatment. Conversely, a small number of women will develop invasive recurrences, raising concerns of under-treatment. Currently, several clinical and pathologic factors have been identified as prognostic markers for recurrence; however, these variables alone have been unable to identify low-risk and high-risk subgroups...
April 21, 2017: Curēus
https://www.readbyqxmd.com/read/28510570/bag-1-as-a-biomarker-in-early-breast-cancer-prognosis-a-systematic-review-with-meta-analyses
#19
REVIEW
E S Papadakis, T Reeves, N H Robson, T Maishman, G Packham, R I Cutress
BACKGROUND: The co-chaperone protein Bcl-2-associated athanogene-1 (BAG-1) is overexpressed in breast cancer and has been incorporated in the oncotype DX and PAM50 breast cancer prognostic assays. Bcl-2-associated athanogene-1 exists as multiple protein isoforms that interact with diverse partners, including chaperones Hsc70/Hsp70, Ser/Thr kinase Raf-1 and Bcl-2, to promote cancer cell survival. The BAG-1L isoform specifically binds to and increases the transcriptional activity of oestrogen receptor in cells, and in some, but not all studies, BAG-1 expression is predictive of clinical outcome in breast cancer...
June 6, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28464832/the-e2f4-prognostic-signature-predicts-pathological-response-to-neoadjuvant-chemotherapy-in-breast-cancer-patients
#20
Kenneth M K Mark, Frederick S Varn, Matthew H Ung, Feng Qian, Chao Cheng
BACKGROUND: Neoadjuvant chemotherapy is a key component of breast cancer treatment regimens and pathologic complete response to this therapy varies among patients. This is presumably due to differences in the molecular mechanisms that underlie each tumor's disease pathology. Developing genomic clinical assays that accurately categorize responders from non-responders can provide patients with the most effective therapy for their individual disease. METHODS: We applied our previously developed E2F4 genomic signature to predict neoadjuvant chemotherapy response in breast cancer...
May 2, 2017: BMC Cancer
keyword
keyword
84415
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"